Tiger Wound Care

Executive Summary

Tiger Wound Care is a vertically integrated, FDA-registered tissue bank and wound care distribution company headquartered in Austin, Texas. The company specializes in placental tissue-based allografts, leveraging science-driven tissue technologies to improve patient outcomes. By controlling the entire supply chain—from tissue procurement to processing and distribution—the company ensures high quality and safety standards. Its mission is to provide healthcare professionals with innovative, safe, and effective tissue-based products for wound management. Despite being a private company with limited public financial data, Tiger Wound Care occupies a niche in the growing biologics wound care market, which is driven by an aging population, rising chronic wound incidence, and demand for advanced therapies. The company's vertical integration and regulatory compliance position it well to capture market share, though its relatively small scale and lack of disclosed funding or valuation may limit visibility. The competitive landscape includes larger players like MiMedx and Organogenesis, but Tiger Wound Care differentiates through its focus on placental allografts and direct distribution model.

Upcoming Catalysts (preview)

• Q3 2026Launch of new placental allograft product for diabetic foot ulcers65% success
• Q4 2026Partnership with major hospital network for nationwide distribution50% success
• Q1 2027FDA clearance for expanded indication of existing allograft line70% success